publication . Article . Review . Other literature type . 2010

Update on the management of chronic eczema: new approaches and emerging treatment options

Hobart W Walling; Brian L Swick;
Open Access
  • Published: 01 Jul 2010 Journal: Clinical, Cosmetic and Investigational Dermatology (eissn: 1178-7015, Copyright policy)
  • Publisher: Dove Medical Press Ltd.
Abstract
Hobart W Walling1, Brian L Swick21Private Practice of Dermatology, Coralville IA, USA; 2University of Iowa Hospitals and Clinics, Departments of Dermatology and Pathology, Iowa City, IA, USAAbstract: Atopic dermatitis (AD) is a common disease with worldwide prevalence, affecting up to 20% of children and 3% of adults. Recent evidence regarding pathogenesis has implicated epidermal barrier defects deriving from filagrin mutations with resulting secondary ­inflammation. In this report, the authors comprehensively review the literature on atopic dermatitis therapy, including topical and systemic options. Most cases of AD will benefit from emollients to enha...
Subjects
free text keywords: Clinical, Cosmetic and Investigational Dermatology, Dermatology, Atopic dermatitis, medicine.disease, medicine, Mepolizumab, medicine.drug, Pimecrolimus, medicine.medical_specialty, business.industry, business, Infliximab, Pathology, Alefacept, Omalizumab, Adalimumab, Tacrolimus, Review, topical corticosteroids, phototherapy, dermatitis, RL1-803
155 references, page 1 of 11

1. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53: S86-S93. [OpenAIRE]

2. Wüthrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol. 1999;83:464-470.

3. Kang K, Polster AM, Nedorost ST, Stevens SR, Cooper KD. Atopic Dermatitis. In: Bolognia J, Jorizzo J, Rapini R, editors. Dermatology. Philadelphia: Mosby; 2003;199-214.

4. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common lossof-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006; 38:441-446.

5. Brown SJ, Irvine AD. Atopic eczema and the filaggrin story. Semin Cutan Med Surg. 2008;27:128-137 6. Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol. 2009;26:14-22.

7. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26:633-640.

8. Hon KL, Ching GK, Leung TF, Choi CY, Lee KK, Ng PC. Estimating emollient usage in patients with eczema. Clin Exp Dermatol. 2010; 35:22-26.

9. Wirén K, Nohlgård C, Nyberg F, et al. Treatment with a barrierstrengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol. 2009;23:1267-1272. [OpenAIRE]

10. Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol. 2008;19:614-618. [OpenAIRE]

11. Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist nurse. Br J Dermatol. 2003;149:582-589. [OpenAIRE]

12. Spergel JM. Immunology and treatment of atopic dermatitis. Am J Clin Dermatol. 2008;9:233-244.

13. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”. J Am Acad Dermatol. 2004;50:391-404. [OpenAIRE]

14. Thomas KS, Armstrong S, Avery A, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ. 2002;324:768.

15. Kantor I, Cook PR, Cullen SI, Willis I, Gibson JR, Stanefild JW. Doubleblind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses. J Am Acad Dermatol. 1991;25:1184-1186.

16. Guzzo CA, Weiss JS, Mogavero HS, et al. A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses. J Am Acad Dermatol. 1991;25:1179-1183.

155 references, page 1 of 11
Abstract
Hobart W Walling1, Brian L Swick21Private Practice of Dermatology, Coralville IA, USA; 2University of Iowa Hospitals and Clinics, Departments of Dermatology and Pathology, Iowa City, IA, USAAbstract: Atopic dermatitis (AD) is a common disease with worldwide prevalence, affecting up to 20% of children and 3% of adults. Recent evidence regarding pathogenesis has implicated epidermal barrier defects deriving from filagrin mutations with resulting secondary ­inflammation. In this report, the authors comprehensively review the literature on atopic dermatitis therapy, including topical and systemic options. Most cases of AD will benefit from emollients to enha...
Subjects
free text keywords: Clinical, Cosmetic and Investigational Dermatology, Dermatology, Atopic dermatitis, medicine.disease, medicine, Mepolizumab, medicine.drug, Pimecrolimus, medicine.medical_specialty, business.industry, business, Infliximab, Pathology, Alefacept, Omalizumab, Adalimumab, Tacrolimus, Review, topical corticosteroids, phototherapy, dermatitis, RL1-803
155 references, page 1 of 11

1. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53: S86-S93. [OpenAIRE]

2. Wüthrich B. Clinical aspects, epidemiology, and prognosis of atopic dermatitis. Ann Allergy Asthma Immunol. 1999;83:464-470.

3. Kang K, Polster AM, Nedorost ST, Stevens SR, Cooper KD. Atopic Dermatitis. In: Bolognia J, Jorizzo J, Rapini R, editors. Dermatology. Philadelphia: Mosby; 2003;199-214.

4. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common lossof-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006; 38:441-446.

5. Brown SJ, Irvine AD. Atopic eczema and the filaggrin story. Semin Cutan Med Surg. 2008;27:128-137 6. Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol. 2009;26:14-22.

7. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26:633-640.

8. Hon KL, Ching GK, Leung TF, Choi CY, Lee KK, Ng PC. Estimating emollient usage in patients with eczema. Clin Exp Dermatol. 2010; 35:22-26.

9. Wirén K, Nohlgård C, Nyberg F, et al. Treatment with a barrierstrengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol. 2009;23:1267-1272. [OpenAIRE]

10. Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol. 2008;19:614-618. [OpenAIRE]

11. Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist nurse. Br J Dermatol. 2003;149:582-589. [OpenAIRE]

12. Spergel JM. Immunology and treatment of atopic dermatitis. Am J Clin Dermatol. 2008;9:233-244.

13. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”. J Am Acad Dermatol. 2004;50:391-404. [OpenAIRE]

14. Thomas KS, Armstrong S, Avery A, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ. 2002;324:768.

15. Kantor I, Cook PR, Cullen SI, Willis I, Gibson JR, Stanefild JW. Doubleblind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatoses. J Am Acad Dermatol. 1991;25:1184-1186.

16. Guzzo CA, Weiss JS, Mogavero HS, et al. A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses. J Am Acad Dermatol. 1991;25:1179-1183.

155 references, page 1 of 11
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue